DDInter1837 DDInter1435
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Toremifene {u} (Compound) resembles {v} (Compound) Doxylamine
Toremifene {u} (Compound) treats {v} (Disease) breast cancer
Toremifene {u} (Compound) binds {v} (Gene) ABCB1
Toremifene {u} (Compound) upregulates {v} (Gene) SQSTM1
Toremifene {u} (Compound) downregulates {v} (Gene) PMM2
Toremifene {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Toremifene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metolazone
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Toremifene (Compound) resembles Doxylamine (Compound)
Toremifene (Compound) treats breast cancer (Disease)
Toremifene (Compound) binds ABCB1 (Gene)
Toremifene (Compound) upregulates SQSTM1 (Gene)
Toremifene (Compound) downregulates PMM2 (Gene)
Toremifene (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Toremifene may lead to a major life threatening interaction when taken with Pazopanib